End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.25 EGP | +1.79% | +2.12% | +32.42% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+32.42% | 193M | B- | ||
-20.48% | 16.2B | B+ | ||
+4.50% | 12.73B | B | ||
+2.99% | 11.68B | B+ | ||
+4.37% | 10.22B | B+ | ||
+28.06% | 8.6B | B | ||
-4.98% | 7.78B | A- | ||
+6.22% | 6.73B | B- | ||
+7.33% | 6.4B | D | ||
+45.44% | 4.49B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- CLHO Stock
- Ratings Cleopatra Hospitals Group S.A.E.